Stage 1-3 - Non-Cirrhosis NASH Trials

Age – Adult (18+)
Gender – Female, Male
Disease Type – Non-Alcoholic Steatohepatitis
Phase – 3
Length of Treatment – 4.5 years
Compensation available.

 

NN9931-4553 The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis

https://clinicaltrials.gov/ct2/show/NCT04822181

Age – Adult (18+)
Gender – Female, Male
Disease Type – Non-Alcoholic Steatohepatitis
Phase – 3a
Length of Treatment – 4.5 years
Compensation available.
 
 

Protocol #:VK2809-202 Protocol Title: VK2809 A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF VK2809 ADMINISTERED FOR 52 WEEKS FOLLOWED BY A 4-WEEK OFF-DRUG PHASE IN SUBJECTS WITH BIOPSY PROVEN NON-ALCOHOLIC STEATOHEPATITIS WITH FIBROSIS

https://clinicaltrials.gov/ct2/show/NCT04173065

Age – Adult (18+)
Gender – Female, Male
Disease Type – Non-Alcoholic Steatohepatitis
Phase – 2b
Length – 52 Weeks
Compensation available.

MGL-3196-11: A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to

Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation
https://www.clinicaltrials.gov/ct2/show/NCT03900429?term=MGL-3196&draw=4&rank=3
Learn More

Additional Information

For more information on what current clinical trials are available at Kansas City Research Institute or additional information and how to get involved, please contact our office phone at (816)759-2574 or send by email at study@kcresearchinstitute.com.

Contact Us